253 related articles for article (PubMed ID: 38198112)
1. Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
Song F; Tarantino P; Garrido-Castro A; Lynce F; Tolaney SM; Schlam I
Curr Oncol Rep; 2024 Jan; 26(1):21-33. PubMed ID: 38198112
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
Dixon-Douglas J; Loi S
Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
[TBL] [Abstract][Full Text] [Related]
3. Current usage of pembrolizumab in triple negative breast cancer (TNBC).
O'Rourke H; Hart C; De Boer RH
Expert Rev Anticancer Ther; 2024 May; 24(5):253-261. PubMed ID: 38594892
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials of immunotherapy in triple-negative breast cancer.
Howard FM; Pearson AT; Nanda R
Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
[TBL] [Abstract][Full Text] [Related]
5. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
6. Current and Future Role of Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: Which Way to Go Forward.
Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35630016
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis.
Cortes J; Haiderali A; Huang M; Pan W; Schmid P; Akers KG; Park JE; Frederickson AM; Fasching PA; O'Shaughnessy J
BMC Cancer; 2023 Aug; 23(1):792. PubMed ID: 37612624
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies and the Evolving Standard of Care for Triple-Negative and Germline
Desai NV; Tan AR
JCO Precis Oncol; 2023 May; 7():e2200446. PubMed ID: 37163718
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy and breast cancer: an overview.
Mezni E; Behi K; Gonçalves A
Curr Opin Oncol; 2022 Sep; 34(5):587-594. PubMed ID: 35838204
[TBL] [Abstract][Full Text] [Related]
11. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple negative breast cancer: How can pathologic responses to experimental drugs in early-stage disease be enhanced?
Giugliano F; Valenza C; Tarantino P; Curigliano G
Expert Opin Investig Drugs; 2022 Aug; 31(8):855-874. PubMed ID: 35762248
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis.
Latif F; Bint Abdul Jabbar H; Malik H; Sadaf H; Sarfraz A; Sarfraz Z; Cherrez-Ojeda I
Expert Rev Anticancer Ther; 2022 Feb; 22(2):229-235. PubMed ID: 34949142
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab and atezolizumab in triple-negative breast cancer.
Kwapisz D
Cancer Immunol Immunother; 2021 Mar; 70(3):607-617. PubMed ID: 33015734
[TBL] [Abstract][Full Text] [Related]
15. Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.
Mohamed A; Kruse M; Tran J
Expert Rev Anticancer Ther; 2023; 23(10):1071-1084. PubMed ID: 37747062
[TBL] [Abstract][Full Text] [Related]
16. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Bonadio RC; Tarantino P; Testa L; Punie K; Pernas S; Barrios C; Curigliano G; Tolaney SM; Barroso-Sousa R
Cancer Treat Rev; 2022 Nov; 110():102459. PubMed ID: 35998514
[TBL] [Abstract][Full Text] [Related]
17. The role of immune checkpoint inhibition in triple negative breast cancer.
Tarekegn K; Keskinkilic M; Kristoff TJ; Evans ST; Kalinsky K
Expert Rev Anticancer Ther; 2023; 23(10):1095-1106. PubMed ID: 37771270
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
20. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response.
De Santis P; Perrone M; Guarini C; Santoro AN; Laface C; Carrozzo D; Oliva GR; Fedele P
Explor Target Antitumor Ther; 2024; 5(1):232-250. PubMed ID: 38464390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
